Robert S. DiPaola, MD
Robert S. DiPaola M.D, is Director of The Cancer Institute of New Jersey and Associate Dean of Oncology Programs at UMDNJ-Robert Wood Johnson Medical School. Dr. DiPaola is a Professor of Medicine and has served as the prior Chief of the Division of Medical Oncology and Associate Director for Clinical Sciences for CINJ. He completed his undergraduate training at the University of Utah, Medical School at the University of Utah School of Medicine, Internal Medicine residency at Duke University Medical Center and Oncology and Hematology training at the University of Pennsylvania, where he also trained in the laboratory of Dr. Alan Gewirtz.
Dr. DiPaola is an active NIH and DOD funded investigator with a focus on translational research and mechanisms of drug resistance in prostate cancer. His specific area of research interest includes targeting apoptosis and metabolism in cancer cells, both in the laboratory and in clinical trials. Nationally, he was elected as the current Chairman of the Genitourinary Committee of the Eastern Cooperative Oncology Group (ECOG), which is responsible for the development of national phase II and III clinical studies in Prostate, Renal, Bladder and Testis cancer. He has also served on several research or educational program committees for the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), and the American Urologic Association (AUA). He currently serves as a full member on the National Cancer Institute's Genitourinary Steering Committee, Investigational Drug Steering Committee, and Clinical Oncology study section.